IHMT-TRK-284 (Compound 34) 是一种有效的、具有口服活性的 type II TRK kinase 抑制剂，对 TRKA, B, C 的 IC50 值分别为 10.5, 0.7和2.6 nM。 IHMT-TRK-284 在激酶组中表现出良好的选择性、具有良好的体内抗肿瘤效果。
IHMT-TRK-284 Chemical Structure
CAS No. : 2416844-79-4
规格
是否有货
100 mg
询价
250 mg
询价
500 mg
询价
* Please select Quantity before adding items.
生物活性
IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies[1].
IC50 & Target
TrkB
0.7 nM (IC50)
TrkC
2.6 nM (IC50)
TrkA
10.5 nM (IC50)
PDGFRα
24.2 nM (IC50)
PDGFRβ
95.7 nM (IC50)
Abl1
83.6 nM (IC50)
CSF1R
1.2 nM (IC50)
KIT
2167 nM (IC50)
体外研究 (In Vitro)
IHMT-TRK-284 (Compound 34) (0-10 µM, 72 h) shows antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells[1]. IHMT-TRK-284 (0-10 µM, 24 h) induces apoptosis and arrests the cell cycle into G0/G1 phase in KM-12-LUC cells[1]. IHMT-TRK-284 exerts its inhibitory effect to the colon cancer cells through on-target inhibition of TRK[1]. IHMT-TRK-284 could overcome drug resistant mutants including V573M and F589L in the ATP binding pocket as well as G667C/S in the DFG region[1]. IHMT-TRK-284 shows selectivity over VEGFR2 kinase[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[1]
Cell Line:
BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells
Concentration:
0-10 µM
Incubation Time:
72 h
Result:
Showed antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells. GI50 for KM-12-LUC cells was 0.002 µM. Antiproliferative effects of IHMT-TRK-284 against a panel of kinase transformed BaF3 cells[1].
Target
GI50 (nM)
BaF3-TEL-ABL
411.1
BaF3-TEL-CSF1R
4
BaF3-TEL-KIT
923.2
BaF3-TEL-PDGFRα
1.7
BaF3-TEL-PDGFRβ
1.4
BaF3-TEL-TRKA
8.5
BaF3-TEL-TRKB
8.2
BaF3-TEL-TRKC
27.3
BaF3-TEL-VEGFR2
1180
Antiproliferative effects of IHMT-TRK-284 against a panel of TRKs wt/mutants transformed BaF3 cells (n = 3)[1].
Cells
GI50 (µM)
BaF3
1.4 ± 0.011
BaF3-LMNA-TRKA
0.007 ± 0.001
BaF3-LMNA-TRKA-V573M
0.003 ± 0.001
BaF3-LMN
Western Blot Analysis[1]
Cell Line:
BaF3-TEL-TRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNATRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C/S, and KM-12-LUC cells
Concentration:
0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time:
2 h
Result:
In transformed BaF3 cells: Inhibited the phosphorylation of TRKA Y490 (EC50 = 0.026 µM) and corresponding tyrosine residues TRKB Y515 (EC50 = 0.069 µM) and TRKC Y516 (EC50 = 0.029 µM); potently inhibited the phosphorylation of Y490 in V573M, F589L, and G667C/S mutants with EC50s of 0.013 µM, 0.021 µM, 0.067 µM, and 0.074 µM respectively. In KM-12-LUC cells: Blocked the phosphorylation of TRKA Y490 at the concentration of 0.01 µM; remarkably inhibited the phosphorylation of downstream signaling mediators AKT T308/S473 and ERK1/2 (T202/Y204) (EC50 less than 0.03 µM).
Apoptosis Analysis[1]
Cell Line:
KM-12-LUC cells
Concentration:
0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time:
24 h
Result:
Induced dose-dependent cell apoptotic death.
Cell Cycle Analysis[1]
Cell Line:
KM-12-LUC cells
Concentration:
0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time:
24 h
Result:
Arrested the cell cycle into G0/G1 phase.
体内研究 (In Vivo)
IHMT-TRK-284 (Compound 34) (40 and 80 mg/kg; p.o.; daily, 10 days) shows good in vivo PK and antitumor efficacy properties[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Four-week old female nu/nu mice, one million BaF3-TELTRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G667S, and five million KM-12-LUC cells in DMEM medium were formulated as a 1:1 mixture with matrigel and injected into the subcutaneous space on the right flank of nu/nu mice[1]
Dosage:
40 mg/kg and 80 mg/kg
Administration:
Daily oral gavage, 10 days
Result:
Dose-dependently inhibited the BaF3-TEL-TRKA, BaF3-TEL-TRKB, and BaF3-TEL-TRKC tumor progression with TGI (tumor growth inhibition) of 68%, 93%, and 58%. Dose-dependently inhibited the tumor progression and exhibited the TGI of 93% at 40 mg/kg/day and 95% at 80 mg/kg/day in KM-12-LUC cells inoculated xenograft mouse model. Potently inhibited the tumor growth with TGI values of 88% and 89% respectively at 80 mg/kg dosage in BaF3- LMNA-TRKA-F589L and BaF3-LMNA-TRKA-G667S cells.
Animal Model:
Mice, sprague dawley rats, and beagle dogs[1]
Dosage:
1 mg/kg and 10 mg/kg
Administration:
Intravenous injection and oral administration (Pharmacokinetic Analysis)
Result:
Pharmacokinetic study of IHMT-TRK-284 in mice, sprague dawley rats, and beagle dogsa[1]
Parameter
Mice i.v. (1 mg/kg)
Mice p.o. (10 mg/kg)
Rats i.v. (1 mg/kg)
Rats p.o. (10 mg/kg)
Beagle Dogs i.v. (1 mg/kg)
Beagle Dogs p.o. (10 mg/kg)
AUC(0-t) (ng/mL*h)
748
1431
393
952
323
464
Tmax (h)
0.033
1.5
0.03
4.7
0.08
4.3
T1/2 (h)
2.6
3.4
2.7
2.5
0.03
11.8
Vz (mL/kg)
4934
31567
9682
分子量
473.59
Formula
C25H27N7OS
CAS 号
2416844-79-4
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Beilei Wang, et al. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. Eur J Med Chem. 2020 Dec 1;207:112744.
DDR-TRK-1 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM. DDR-TRK-1 also inhibits TRK family.
IC50 & Target
IC50: 9.4 nM (DDR1)[1].
体外研究 (In Vitro)
DDR-TRK-1 is a promising candidate, with an IC50 value of 9.4 nM against DDR1. DDR-TRK-1 also exhibits reasonable pharmacokinetic (PK) properties, with an oral bioavailability of 66.8% and a T1/2 value of 1.25 h at an oral dose of 20 mg/kg in rats. However, the area under concentration−time curve (AUC) value of DDR-TRK-1 in mice is obviously higher than that in rats, suggesting its good absorption property in mice. The DDR1 inhibition of DDR1-IN-3 is further validated by determining its binding affinity with the DDR1 protein. It is shown that DDR-TRK-1 bounds tightly to DDR1, with a binding constant (Kd) value of 4.7 nM[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
DDR-TRK-1 prevents these BLM-induced pathological changes in a dose-dependent manner. These results agree with the expression levels of fibrotic markers in lung tissue lysates, including fibronectin and α-smooth muscle actin (SMA). Further analyses also reveal that the administration of DDR-TRK-1 cause a dose-dependent suppression in the content of hydroxyproline, a unique amino acid found in collagen. The above data collectively indicate the promising therapeutic potential of DDR-TRK-1 against the BLM-induced pulmonary fibrosis[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量
492.50
Formula
C26H23F3N6O
CAS 号
1934246-19-1
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Zhen Wang, et al. Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. J Med Chem. 2016 Jun 23; 59(12): 5911–5916.
Cell Assay [1]
Panc-1 cells are plated at low density in media in the presence or absence of controls or the indicated concentration of DDR-TRK-1 (0.016, 0.0625, 0.25, 1 μM). Colony formation is evaluated after 1.5-2 weeks by fixing and staining with crystal violet. The effect of DDR1-IN-3 on cell migration is determined through a ‘scratch’ assay. Panc-1 cells are grown to confluence in a 6 well dish. A scratch is made using a p20 pipette tip and cell migration into the wound is determined at 12, 24, 48, 60, and 72 hrs. The effect of control compounds or DDR-TRK-1 at the indicated concentrations is determined at each time point[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration [1]
Mice[1] To induce pulmonary damage, 6- to 8-week-old sex- and age-matched wild type or slie mice (at least five animals per group) are intranasally dropped with bleomycin at 5mg/kg BW. The inhibitors (e.g., DDR-TRK-1) are dissolved in water at a concentration of 5 mg/mL and given to the mice orally by gavage twice a day. Hydroxyproline accounts for 13.4% of the total amino acids of collagen; thus its content can be used to reflect the severity of fibrosis. A commercial hydroxyproline kit is used. Briefly, fresh lung tissues are weighted and hydrolyzed to release hydroxyproline. After a series of chemical reactions, a pink color solution is formed and then subjected to measurement of absorbance at 560 nm. The hydroxyproline content of each sample is calculated by comparing with the standards[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献
[1]. Zhen Wang, et al. Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. J Med Chem. 2016 Jun 23; 59(12): 5911–5916.
Trk-IN-6 shows excellent in vitro potency on a panel of TRK mutants (IC50 = 0.2-0.7 nM).
分子量
446.43
Formula
C21H21F3N6O2
CAS 号
2489327-43-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Zhuo LS, et al. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation. J Med Chem. 2021 Oct 28;64(20):15503-15514.
Trk-IN-6 shows excellent in vitro potency on a panel of TRK mutants (IC50 = 0.2-0.7 nM).
分子量
446.43
Formula
C21H21F3N6O2
CAS 号
2489327-43-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Zhuo LS, et al. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation. J Med Chem. 2021 Oct 28;64(20):15503-15514.
Trk-IN-6 shows excellent in vitro potency on a panel of TRK mutants (IC50 = 0.2-0.7 nM).
分子量
446.43
Formula
C21H21F3N6O2
CAS 号
2489327-43-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Zhuo LS, et al. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation. J Med Chem. 2021 Oct 28;64(20):15503-15514.
TRK-IN-19 (Compound I-10 ) is a potent inhibitor of TRK (TRKA IC50 = 1.1 nM, TRKAG595RIC50 = 5.3 nM). TRK-IN-19 has the potential for the research of cancer diseases[1].
分子量
411.47
Formula
C22H26FN5O2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Sun M, et al. Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors. Bioorg Med Chem. 2020 Dec 1;28(23):115811. doi: 10.1016/j.bmc.2020.115811.
Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-Trk and their drug-resistant mutants with IC50 values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against TrkA, TrkB, TrkC, TrkAG595R, TrkAG667C, TrkAG667S, TrkAF589L and TrkCG623R, respectively. Pan-Trk-IN-3 displays excellent antitumor activity and induces apoptosis[1].
IC50 & Target
TrkA
2 nM (IC50)
TrkC
2 nM (IC50)
TrkB
3 nM (IC50)
TrkAG667S
5 nM (IC50)
TrkCG623R
6 nM (IC50)
TrkAF589L
7 nM (IC50)
TrkAG595R
21 nM (IC50)
TrkAG667C
26 nM (IC50)
分子量
575.06
Formula
C29H31ClN8O3
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Pan S,et al. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants. J Med Chem. 2022 Feb 10;65(3):2035-2058.
Compound cpd-1 is a small molecule Trks inhibitor with good antitumor activity[1].
分子量
506.86
Formula
C22H18ClF3N6O3
CAS 号
2583778-77-0
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Pan S,et al. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants. J Med Chem. 2022 Feb 10;65(3):2035-2058.
TRK-IN-14 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-14 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-47)[1].
分子量
433.45
Formula
C24H21F2N5O
CAS 号
1365212-84-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Yi Fan, et al. Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors. Patent WO2012034091A1.
TRK-IN-16 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-16 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-21)[1].
分子量
353.39
Formula
C19H20FN5O
CAS 号
1365212-81-2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Yi Fan, et al. Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors. Patent WO2012034091A1.
TRK-IN-18 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7)[1].
分子量
495.54
Formula
C25H23F2N5O2S
CAS 号
2412008-91-2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
TRK-IN-13 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-13 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-24)[1].
分子量
433.45
Formula
C24H21F2N5O
CAS 号
1365221-52-8
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Yi Fan, et al. Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors. Patent WO2012034091A1.
TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of TRK and ALK. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC50 values of 2.2, 9.3 and 38 nM towards TRKA, ALKWT and ALKL1196M, respectively. TRK/ALK-IN-1 has the potential for the research of cancer diseases[1].
分子量
657.18
Formula
C31H35ClF2N8O2S
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Li T, et al. Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. Bioorg Med Chem. 2021 Oct 1;47:116396.
TRK-IN-15 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-15 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-55)[1].
分子量
353.39
Formula
C19H20FN5O
CAS 号
1365213-20-2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Yi Fan, et al. Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors. Patent WO2012034091A1.
TRK-IN-17 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3)[1].
分子量
441.50
Formula
C21H21F2N7S
CAS 号
2409544-80-3
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Nicola ROBAS, et al. Pharmaceutical compositions and their uses. Patent WO2021148807A1.
Trk-IN-7 (compound I-6) is a potent TRK inhibitor with IC50s of ranging from 0.25-10 nM for TRKA, TRKB and TRKC, respectively. Trk-IN-7 shows inhibition against EML4-ALK (IC50<15 nm) alk g1202r, c1156y, r1275q, f1174l, l1197m, and g1269a (IC50=5-50 nM)[1].
IC50 & Target[1]
TrkA
<25 nM (IC50)
TrkB
<5 nM (IC50)
TrkC
<25 nM (IC50)
分子量
368.36
Formula
C18H17FN6O2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Diaryl macrocyclic compound as protein kinase modulator. WO2019210835A1.
Trk-IN-8 is a potent TRK inhibitor with IC50s of 0.42, 0.89 and 1.5 nM for TRKAa, TRKA(G595R) and TRKC(G623R), respectively (WO2021115401A1, compound 3)[1].
分子量
386.36
Formula
C18H16F2N6O2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof. WO2021115401A1.
Trk-IN-7 (compound I-6) is a potent TRK inhibitor with IC50s of ranging from 0.25-10 nM for TRKA, TRKB and TRKC, respectively. Trk-IN-7 shows inhibition against EML4-ALK (IC50<15 nm) alk g1202r, c1156y, r1275q, f1174l, l1197m, and g1269a (IC50=5-50 nM)[1].
IC50 & Target[1]
TrkA
<25 nM (IC50)
TrkB
<5 nM (IC50)
TrkC
<25 nM (IC50)
分子量
368.36
Formula
C18H17FN6O2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Diaryl macrocyclic compound as protein kinase modulator. WO2019210835A1.
Trk-IN-8 is a potent TRK inhibitor with IC50s of 0.42, 0.89 and 1.5 nM for TRKAa, TRKA(G595R) and TRKC(G623R), respectively (WO2021115401A1, compound 3)[1].
分子量
386.36
Formula
C18H16F2N6O2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof. WO2021115401A1.
Trk-IN-7 (compound I-6) is a potent TRK inhibitor with IC50s of ranging from 0.25-10 nM for TRKA, TRKB and TRKC, respectively. Trk-IN-7 shows inhibition against EML4-ALK (IC50<15 nm) alk g1202r, c1156y, r1275q, f1174l, l1197m, and g1269a (IC50=5-50 nM)[1].
IC50 & Target[1]
TrkA
<25 nM (IC50)
TrkB
<5 nM (IC50)
TrkC
<25 nM (IC50)
分子量
368.36
Formula
C18H17FN6O2
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Diaryl macrocyclic compound as protein kinase modulator. WO2019210835A1.
